158 related articles for article (PubMed ID: 37440955)
41. Mycoplasma infection promotes tumor progression via interaction of the mycoplasmal protein p37 and epithelial cell adhesion molecule in hepatocellular carcinoma.
Kim MK; Shin SJ; Lee HM; Choi HS; Jeong J; Kim H; Paik SS; Kim M; Choi D; Ryu CJ
Cancer Lett; 2019 Jul; 454():44-52. PubMed ID: 30980864
[TBL] [Abstract][Full Text] [Related]
42. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy.
Xu W; Cao L; Chen L; Li J; Zhang XF; Qian HH; Kang XY; Zhang Y; Liao J; Shi LH; Yang YF; Wu MC; Yin ZF
Clin Cancer Res; 2011 Jun; 17(11):3783-93. PubMed ID: 21527564
[TBL] [Abstract][Full Text] [Related]
43. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
[TBL] [Abstract][Full Text] [Related]
44. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.
Chen J; Cao SW; Cai Z; Zheng L; Wang Q
Cancer Biomark; 2017 Dec; 20(4):487-498. PubMed ID: 28869439
[TBL] [Abstract][Full Text] [Related]
45. Circulating tumor cells and CXCR4 in the prognosis of hepatocellular carcinoma.
Bai T; Mai R; Ye J; Chen J; Qi L; Tang J; Wei M; Zhang L; Chen Z; Tang Z; Li L; Wu F
Transl Cancer Res; 2020 Mar; 9(3):1384-1394. PubMed ID: 35117486
[TBL] [Abstract][Full Text] [Related]
46. Cellular, Molecular and Proteomic Characteristics of Early Hepatocellular Carcinoma.
Armakolas A; Dimopoulou V; Nezos A; Stamatakis G; Samiotaki M; Panayotou G; Tampaki M; Stathaki M; Dourakis S; Koskinas J
Curr Issues Mol Biol; 2022 Oct; 44(10):4714-4734. PubMed ID: 36286037
[TBL] [Abstract][Full Text] [Related]
47. The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma.
Yi B; Wu T; Zhu N; Huang Y; Yang X; Yuan L; Wu Y; Liang X; Jiang X
J Nanobiotechnology; 2021 Mar; 19(1):74. PubMed ID: 33726759
[TBL] [Abstract][Full Text] [Related]
48. Effect of various hepatectomy procedures on circulating tumor cells in postoperative patients: a case-matched comparative study.
Lei Y; Wang X; Tian Y; Xu R; Pei J; Fu Y; Sun H; Wang Y; Zheng P; Xia F; Wang J
Front Med (Lausanne); 2023; 10():1209403. PubMed ID: 37841010
[TBL] [Abstract][Full Text] [Related]
49. Multicolor detection of rare tumor cells in blood using a novel flow cytometry-based system.
Watanabe M; Uehara Y; Yamashita N; Fujimura Y; Nishio K; Sawada T; Takeda K; Koizumi F; Koh Y
Cytometry A; 2014 Mar; 85(3):206-13. PubMed ID: 24327318
[TBL] [Abstract][Full Text] [Related]
50. Anterior Approach to Improve the Prognosis in HCC Patients Via Decreasing Dissemination of EpCAM
Hao S; Chen S; Tu C; Huang T
J Gastrointest Surg; 2017 Jul; 21(7):1112-1120. PubMed ID: 28378318
[TBL] [Abstract][Full Text] [Related]
51. Biofunctionalized magnetic nanospheres-based cell sorting strategy for efficient isolation, detection and subtype analyses of heterogeneous circulating hepatocellular carcinoma cells.
Chen L; Wu LL; Zhang ZL; Hu J; Tang M; Qi CB; Li N; Pang DW
Biosens Bioelectron; 2016 Nov; 85():633-640. PubMed ID: 27240010
[TBL] [Abstract][Full Text] [Related]
52. Circulating AFP mRNA as a Possible Indicator of Hematogenous Spread of HCC Cells: A Possible Association with HBV Infection.
Montaser LM; Abbas OM; Saltah AM; Waked IA
J Egypt Natl Canc Inst; 2007 Mar; 19(1):48-60. PubMed ID: 18839035
[TBL] [Abstract][Full Text] [Related]
53. The Presence of Circulating Tumor Cell Cluster Characterizes an Aggressive Hepatocellular Carcinoma Subtype.
Yu JJ; Shu C; Yang HY; Huang Z; Li YN; Tao R; Chen YY; Chen Q; Chen XP; Xiao W
Front Oncol; 2021; 11():734564. PubMed ID: 34722281
[TBL] [Abstract][Full Text] [Related]
54. Tumor-derived proliferative CTCs and CTC clusters predict aggressiveness and early recurrence in hepatocellular carcinoma patients.
Zhao L; Song J; Sun Y; Ju Q; Mu H; Dong X; Ding J; Liu Y; Wang X; Sun L; Wu J; Jiao Y; Lu S; Zhao X
Cancer Med; 2023 Jul; 12(13):13912-13927. PubMed ID: 37337648
[TBL] [Abstract][Full Text] [Related]
55. Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay.
Zhang Y; Zhang X; Zhang J; Sun B; Zheng L; Li J; Liu S; Sui G; Yin Z
Cancer Biol Ther; 2016 Nov; 17(11):1177-1187. PubMed ID: 27662377
[TBL] [Abstract][Full Text] [Related]
56. Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients.
Gatselis NK; Tornai T; Shums Z; Zachou K; Saitis A; Gabeta S; Albesa R; Norman GL; Papp M; Dalekos GN
World J Gastroenterol; 2020 Sep; 26(34):5130-5145. PubMed ID: 32982114
[TBL] [Abstract][Full Text] [Related]
57. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.
Chen VL; Xu D; Wicha MS; Lok AS; Parikh ND
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2879-2902.e9. PubMed ID: 32289533
[TBL] [Abstract][Full Text] [Related]
58. Circulating tumor cell enumeration for improved screening and disease detection of patients with colorectal cancer.
Tsai WS; Hung WS; Wang TM; Liu H; Yang CY; Wu SM; Hsu HL; Hsiao YC; Tsai HJ; Tseng CP
Biomed J; 2021 Dec; 44(6 Suppl 2):S190-S200. PubMed ID: 35292267
[TBL] [Abstract][Full Text] [Related]
59. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
[TBL] [Abstract][Full Text] [Related]
60. Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma.
Teng PC; Agopian VG; Lin TY; You S; Zhu Y; Tseng HR; Yang JD
J Gastroenterol Hepatol; 2022 Jul; 37(7):1179-1190. PubMed ID: 35543075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
